Data on Kappaproct for Ulcerative Colitis to be Presented at 2016 United European Gastroenterology Week

Data on Kappaproct for Ulcerative Colitis to be Presented at 2016 United European Gastroenterology Week
InDex Pharmaceuticals will present additional data from its trial that investigated Kappaproct (cobitolimod) for treatment of moderate to severe active ulcerative colitis (UC). The data will be presented by Raja Atreya, a professor at the University of Erlangen-Nürnberg, during United European Gastroenterology Week (UEGW), Oct. 15-19, in Vienna. COLLECT (NCT01493960) was a placebo-controlled, double-blind, randomized study that assessed the effectiveness and safety of Kappaproct in 131 chronic active ulcerative colitis patients who had not responded to available therapy. COLLECT was conducted at 38 centers in seven European countries. Patients received either two single rectal 30 mg doses of Kappaproct or a placebo four weeks apart. They were followed for 12 weeks. The primary endpoint was clinical remission, defined by the Clinical Activity Index (CAI), at week 12. Secondary endpoints included mucosal healing and symptomatic remission (absence of blood in stool and weekly stool frequency of less than 35). The results supporting Kappaproct as a novel treatment for moderate to severe active UC were recently published in the Journal of Crohn’s and Colitis (JCC), in a study report titled “Clinical effects of a topically applied Toll- receptor 9 agonist in active moderate to severe ulcerative colitis.” The published data shows statistically significant differences between patients treated with the drug versus those treated with placebo. The proportion of patients who achieved symptomatic remission was 32.1% versus 14% at week 4, respectively, and 44.4%  versus 27.9% at week 8, respectively. In addition, at week 4, more patients treated with Kappaproct compared to placebo had mucosal healing (34.6% versus 18.6%) and histological improvement
Subscribe or to access all post and page content.